The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.
May 16th 2024
The FDA will hold an end-of-phase 2 meeting to discuss botensilimab plus balstilimab for the treatment of patients with relapsed/refractory metastatic colorectal cancer.
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
ctDNA and MRD Testing in Nonmetastatic Colorectal Cancer
A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.
Biomarker Testing in Metastatic Colorectal Cancer
Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.
Dr Taieb on Findings from a Post-hoc Analysis of TAS-102 Plus Bevacizumab in Refractory mCRC
June 20th 2023Julien Taieb, MD, PhD, discusses key findings from a post-hoc analysis of the phase 3 SUNLIGHT trial of combination of trifluridine/tipiracil with bevacizumab in patients with refractory metastatic colorectal cancer.
DESTINY-CRC02 Trial Continues to Support the Use of T-DXd in HER2+ Metastatic CRC
June 19th 2023Kanwal Pratap Singh Raghav MBBS, MD, discusses data from DESTINY-CRC01 that supported the DESTINY-CRC02 trial, key efficacy and safety data from the trial, and the importance of identifying patients with HER2-positive CRC who may benefit from ADCs like T-DXd in clinical practice.
European Medicines Agency Validates MAA for Fruquintinib in Pretreated mCRC
June 16th 2023The European Medicines Agency has validated and accepted a marketing authorization application for priority review for fruquintinib for the treatment of adult patients with pretreated metastatic colorectal cancer.
Dr Hitchcock on the Rationale for the ERAsur Trial in Limited mCRC
June 15th 2023Kathryn Hitchcock, MD, PhD, discusses the rationale for the ongoing phase 3 ERAsur trial investigating total ablative therapy in patients with limited metastatic colorectal cancer and details the methodologies being used in this study.
FDA Greenlights Companion Diagnostic for Encorafenib Plus Cetuximab in BRAF V600E+ mCRC
The FDA has approved FoundationOne CDx for use as a companion diagnostic to determine patients with BRAF V600E–mutated metastatic colorectal cancer who may be candidates to receive encorafenib in combination with cetuximab.
Understanding Lynch Syndrome and Associated Cancer Risk: Future Preventive Considerations
June 7th 2023In this sixth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, shares future considerations for optimizing the identification of Lynch syndrome and other efforts underway to prevent colorectal cancer in those who have this condition.
Fruquintinib/BSC Demonstrates OS/PFS Benefit in Refractory mCRC, Irrespective of Prior Treatment
Treatment with fruquintinib plus best supportive care led to improved overall survival and progression-free survival vs placebo plus best supportive care in patients with refractory metastatic colorectal cancer, irrespective of number of prior lines of therapy or type of prior treatment.
Dr Raghav on Trastuzumab Deruxtecan in HER2+ mCRC
June 4th 2023Kanwal P. S. Raghav, MBBS, MD, discusses primary findings from the phase 2 DESTINY-CRC02 trial (NCT04744831) of fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with metastatic colorectal cancer with HER2 amplification or overexpression.
Understanding Lynch Syndrome and Associated Cancer Risk: Treatment Advances
May 31st 2023In this fifth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, highlights progress made with regard to colon cancer treatment and Lynch syndrome, including leveraging immunotherapy.
Encorafenib Plus Cetuximab/Binimetinib Displays Activity, Safety in BRAF V600E–mutant mCRC
Triplet therapy consisting of encorafenib, cetuximab, and binimetinib demonstrated activity and manageable safety as first-line treatment for patients with BRAF V600E–mutated metastatic colorectal cancer.
Preliminary Data Show Improved Responses with Cetuximab Plus Divarasib in KRAS G12C–mutated CRC
May 16th 2023Jayesh Desai, MBBS, FRACP, reports prior phase 1 data on the use of divarasib monotherapy in KRAS G12C–mutated CRC and early efficacy, safety, and presents pharmacokinetic data from the use of divarasib plus cetuximab from a phase 1 trial.
IBI351 Receives Breakthrough Therapy Designation in China for Previously Treated Advanced CRC
China’s National Medical Products Administration has granted a breakthrough therapy designation to the KRAS G12C inhibitor IBI351 as monotherapy for previously treated patients with advanced colorectal carcinoma harboring a KRAS G12C mutation.
Understanding Lynch Syndrome and Associated Cancer Risk: Epidemiology
May 10th 2023In this second episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, delves into the epidemiology of Lynch syndrome, the pathogenic variants in the mismatch-repair genes that cause the condition, and criteria utilized to identify it.
Continued Development of Targeted Therapies Aims to Address Unmet Needs in CRC
John L. Marshall, MD, discusses the identification of targetable subsets of patients with advanced CRC, unmet needs that remain to be addressed for patients with advanced CRC, and the continued need for a multidisciplinary approach in treating patients across the gastrointestinal cancer spectrum.